Pifeltro (doravirine) vs Sunlenca (lenacapavir)
Pifeltro (doravirine) vs Sunlenca (lenacapavir)
Pifeltro (doravirine) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults with no prior antiretroviral treatment history. Sunlenca (lenacapavir) is a novel HIV-1 capsid inhibitor with a unique mechanism of action and a long-acting formulation, allowing for dosing every six months after an initial loading phase, and is used in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection. When deciding between Pifeltro and Sunlenca, it is crucial to consider factors such as the stage of HIV infection, previous treatment history, resistance patterns, dosing frequency preference, and the potential for drug-drug interactions.
Difference between Pifeltro and Sunlenca
Metric | Pifeltro (doravirine) | Sunlenca (lenacapavir) |
---|---|---|
Generic name | Doravirine | Lenacapavir |
Indications | HIV-1 infection in adults | HIV-1 infection in adults |
Mechanism of action | Non-nucleoside reverse transcriptase inhibitor (NNRTI) | HIV-1 capsid inhibitor |
Brand names | Pifeltro | Sunlenca |
Administrative route | Oral | Subcutaneous and intramuscular |
Side effects | Nausea, dizziness, abnormal dreams, fatigue | Injection site reactions, nausea, fatigue, headache |
Contraindications | Coadministration with drugs that are strong CYP3A inducers | Coadministration with strong CYP3A inducers or drugs that increase gastric pH |
Drug class | NNRTI | HIV-1 capsid inhibitor |
Manufacturer | Merck & Co. | Gilead Sciences |
Efficacy
Pifeltro (Doravirine) for HIV/AIDS
Pifeltro, which contains the active ingredient doravirine, is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV-1 infection in adults. This medication is typically prescribed in combination with other antiretroviral agents. Clinical trials have demonstrated that Pifeltro is effective in reducing viral loads in individuals with HIV-1. In a pivotal phase 3 clinical trial, doravirine was found to be non-inferior to a comparator NNRTI, efavirenz, when used in combination with other antiretroviral drugs. Patients treated with Pifeltro showed a significant reduction in viral load and an increase in CD4+ T-cell counts, which are critical markers of immune health in the context of HIV/AIDS.
Sunlenca (Lenacapavir) for HIV/AIDS
Sunlenca, with the active ingredient lenacapavir, is a first-in-class HIV-1 capsid inhibitor that has shown promise in the treatment of HIV-1 infection. As a novel antiretroviral agent, lenacapavir disrupts multiple stages of the HIV-1 lifecycle, including capsid assembly and disassembly, nuclear import, and viral DNA integration. The efficacy of Sunlenca has been evaluated in clinical studies involving heavily treatment-experienced individuals with multidrug-resistant HIV-1 infection. Results from these studies have shown that lenacapavir, when administered in combination with other antiretrovirals, led to substantial reductions in viral load and was generally well-tolerated by patients.
Both Pifeltro and Sunlenca are part of the modern arsenal of antiretroviral therapies that have transformed HIV/AIDS from a once fatal diagnosis to a manageable chronic condition. Their distinct mechanisms of action complement the existing treatments, offering additional options for individuals with HIV/AIDS, particularly those who may have developed resistance to other medications. The continued development and approval of such innovative treatments underscore the progress being made in the fight against HIV/AIDS and the importance of personalized medicine in achieving optimal patient outcomes.
It is important for healthcare providers to consider the individual needs of their patients when prescribing these medications, including potential drug-drug interactions, resistance patterns, and the patient's treatment history. The efficacy of Pifeltro and Sunlenca in improving the health and longevity of individuals with HIV/AIDS is a testament to the ongoing research and dedication to finding effective treatments for this chronic disease. As with all medications, the use of Pifeltro and Sunlenca should be guided by current clinical guidelines and the expertise of healthcare professionals specializing in the treatment of HIV/AIDS.
Regulatory Agency Approvals
Pifeltro
Sunlenca
Access Pifeltro or Sunlenca today
If Pifeltro or Sunlenca are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us